Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649519 | Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg | PHASE1 | COMPLETED | 54 | — | — | May 1, 2004 | May 1, 2004 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Amlodipine and Benazepril HCl Capsules 10 mg/20 mg |
| 2 | ACTIVE_COMPARATOR | Lotrel® Capsules 10 mg/20 mg |
| Name | Type | Description |
|---|---|---|
| Amlodipine and Benazepril HCl Capsules 10 mg/20 mg | DRUG | 10/20mg, single dose fasting |
| Lotrel® Capsules 10 mg/20 mg | DRUG | 10/20mg, single dose fasting |
Inclusion Criteria: * 1\. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the eve...